Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Spikevax COVID-19 Vaccine Coverage Update

Last updated on

Beginning June 1, 2022, Medicaid will cover the brand name Spikevax COVID-19 vaccine national drug codes (NDCs) for Medicaid and the Children’s Health Insurance Program (CHIP) as a payable pharmacy benefit. Spikevax is the brand name for the Moderna COVID-19 vaccine and has its own unique NDC.

On January 31, 2022, the U.S. Food and Drug Administration (FDA) issued full approval of the Moderna COVID-19 vaccine, now marketed as Spikevax, for individuals 18 years of age or older. Spikevax has the same formulation as the emergency use authorization (EUA) Moderna COVID-19 vaccine and the same administration schedule in which the primary series of two doses is given by a health-care provider with one month between doses. The original Moderna COVID-19 vaccine is also available under the EUA. Spikevax can be used interchangeably with the EUA Moderna COVID-19 vaccine without presenting any safety or effectiveness concerns.

The following NDCs have been added to the formulary for Medicaid and CHIP as a reimbursable pharmacy benefit:

Drug Name



Spikevax COVID-19 Vaccine

0.5 mL


Spikevax COVID-19 Vaccine

0.5 mL


Email comments or questions to